Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
- 29 February 2008
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 196 (2) , 659-666
- https://doi.org/10.1016/j.atherosclerosis.2007.07.022
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Molecular biology of PCSK9: its role in LDL metabolismTrends in Biochemical Sciences, 2007
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic miceJournal of Clinical Investigation, 2006
- Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound HeterozygoteAmerican Journal of Human Genetics, 2006
- Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease riskJournal of Medical Genetics, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences, 2005
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003
- Development of a microsatellite-based approach to co-segregation analysis of familial hypercholesterolaemic kindredsAnnals of Human Genetics, 1997